Sign Up Today and Learn More About Regenacy Pharmaceuticals Stock
Invest in or calculate the value of your shares in Regenacy Pharmaceuticals or other pre-IPO companies through EquityZen's platform.
Regenacy Pharmaceuticals Stock (REPH)
Regenacy Pharmaceuticals Provides Healthcare Services.
About Regenacy Pharmaceuticals Stock
Founded
2016
Headquarters
Waltham, MA, US
Industries
Software, Artificial Intelligence, Data and Analytics
Regenacy Pharmaceuticals Press Mentions
Stay in the know about the latest news on Regenacy Pharmaceuticals
Chemotherapy Induced Peripheral Neuropathy Treatment Market Forecast Report 2025 | Profiling Key Innovators in CIPN Therapeutics
globenewswire • Jun 04, 2025
Histone Deacetylase (HDAC) 6 Pipeline Landscape 2025: In-Depth Insights Into Over 20 Companies and 26 Drugs Within the HDAC 6 Inhibitors Pipeline
globenewswire • May 08, 2025
Diabetic Peripheral Neuropathy Market Report 2025-2035 - Pharmacological and Non-Pharmacological Innovations Expand Treatment Landscape for Diabetic Neuropathy
globenewswire • May 07, 2025
Piperidine derivatives as hdac1/2 inhibitors
patents • Apr 14, 2024
Substituted piperazines as selective hdac1,2 inhibitors
patents • Apr 14, 2024
Regenacy Pharmaceuticals Management
Leadership team at Regenacy Pharmaceuticals
Co-Founder & Executive Chairman
Marc Cohen
Clinical Consultant
Michelle Hylan
Join now and verify your accreditation status to gain access to:
- Regenacy Pharmaceuticals Current Valuation
- Regenacy Pharmaceuticals Stock Price
- Regenacy Pharmaceuticals Management
- Available deals in Regenacy Pharmaceuticals and all other companies with relevant Deal Offering documents
- EquityZen's proprietary data and insights, which may include
- Regenacy Pharmaceuticals Cap Table and Funding History by Share Class and Liquidity Preferences
- Regenacy Pharmaceuticals Revenue and Financials
- Regenacy Pharmaceuticals Highlights
- Regenacy Pharmaceuticals Business Model
- Regenacy Pharmaceuticals Risk Factors
- Regenacy Pharmaceuticals Research Report from SACRA Research
Trading Regenacy Pharmaceuticals Stock
How to invest in Regenacy Pharmaceuticals stock?
Accredited investors can buy pre-IPO stock in companies like Regenacy Pharmaceuticals through EquityZen funds. These investments are made available by existing Regenacy Pharmaceuticals shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process for buying Pre-IPO Shares.
How to sell Regenacy Pharmaceuticals stock?
Shareholders can sell their Regenacy Pharmaceuticals stock through EquityZen's private company marketplace. EquityZen's network includes over 440K accredited investors interested in buying private company stock. Learn more about the Shareholder liquidity process.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. See more information on Express Deals and pre-IPO exit information.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 53K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
